Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Assets Average: 2022-2025

Historic Assets Average for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $654.5 million.

  • Axsome Therapeutics' Assets Average rose 17.96% to $654.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654.5 million, marking a year-over-year increase of 17.96%. This contributed to the annual value of $578.4 million for FY2024, which is 25.77% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Assets Average of $654.5 million as of Q3 2025, which was up 5.87% from $618.2 million recorded in Q2 2025.
  • Axsome Therapeutics' Assets Average's 5-year high stood at $654.5 million during Q3 2025, with a 5-year trough of $134.6 million in Q2 2022.
  • Over the past 3 years, Axsome Therapeutics' median Assets Average value was $567.0 million (recorded in 2024), while the average stood at $559.1 million.
  • Its Assets Average has fluctuated over the past 5 years, first spiked by 271.89% in 2023, then decreased by 8.48% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Assets Average (Quarterly) stood at $335.2 million in 2022, then surged by 77.36% to $594.5 million in 2023, then declined by 4.97% to $565.0 million in 2024, then increased by 17.96% to $654.5 million in 2025.
  • Its last three reported values are $654.5 million in Q3 2025, $618.2 million for Q2 2025, and $582.6 million during Q1 2025.